<div class="floatDisplay"><div class="table-wrap" id="tbl3">
<table>
<caption tabindex="0">
<span class="label">Table 3</span><span>Statistical analysis of the proportion of responders<a href="#title-footnote-tbl3fna" id="back-title-footnote-tbl3fna" class="figureLink"><sup>a</sup></a><span class="crossref-label" style="display: none;"></span> on individual EQ-5D-3L descriptive dimensions (Week 52 data<a href="#title-footnote-tbl3fnb" id="back-title-footnote-tbl3fnb" class="figureLink"><sup>b</sup></a><span class="crossref-label" style="display: none;"></span>; overall study population).</span>
</caption>
<tbody>
<tr>
<th scope="col" rowspan="3">EQ-5D-3L dimension</th>
<th scope="col" colspan="2">Baseline</th>
<th scope="col" colspan="3">Week 52</th>
</tr>
<tr>
<th scope="col" colspan="2">Patients, n/N (%)</th>
<th scope="col" colspan="2">Patients, n/N (%)</th>
<th scope="col" rowspan="2">Adjusted OR (95% CI)<a href="#title-footnote-tbl3fnc" id="back-title-footnote-tbl3fnc" class="figureLink"><sup>c</sup></a><span class="crossref-label" style="display: none;"></span> p-value</th>
</tr>
<tr>
<th scope="col">FF/VI (n = 2114)</th>
<th scope="col">UC (n = 2119)</th>
<th scope="col">FF/VI (n = 2114)</th>
<th scope="col">UC (n = 2119)</th>
</tr>
<tr>
<td>Mobility</td>
<td>1429/2113 (68)</td>
<td>1416/2119 (67)</td>
<td>1417/1984 (71)</td>
<td>1330/1988 (67)</td>
<td>1.35 (1.15–1.60)<br><br><em>p</em> &lt; .001</td>
</tr>
<tr>
<td>Self-care</td>
<td>1882/2113 (89)</td>
<td>1882/2119 (89)</td>
<td>1747/1984 (88)</td>
<td>1757/1988 (88)</td>
<td>0.90 (0.71–1.15)<br><br><em>p</em> = .409</td>
</tr>
<tr>
<td>Usual activities</td>
<td>1394/2113 (66)</td>
<td>1354/2119 (64)</td>
<td>1416/1984 (71)</td>
<td>1352/1988 (68)</td>
<td>1.20 (1.02–1.40)<br><br><em>p</em> = .027</td>
</tr>
<tr>
<td>Pain/discomfort</td>
<td>1120/2113 (53)</td>
<td>1190/2119 (56)</td>
<td>1152/1984 (58)</td>
<td>1113/1988 (56)</td>
<td>1.16 (1.01–1.34)<br><br><em>p</em> = .043</td>
</tr>
<tr>
<td>Anxiety/depression</td>
<td>1443/2113 (68)</td>
<td>1445/2119 (68)</td>
<td>1396/1984 (70)</td>
<td>1360/1988 (68)</td>
<td>1.11 (0.95–1.30)<br><br><em>p</em> = .180</td>
</tr>
</tbody>
</table>
<a href="javascript:void(0)" class="tableLink" onclick="window.open('/action/showFullTableImage?isHtml=true&amp;tableId=tbl3&amp;pii=S095461111830194X', '_blank')">
                        View Table in HTML
                    </a><div class="footnote"><p>Abbreviations: CI, 
confidence interval; EQ-5D-3L, EuroQol 5-Dimensions 3-Levels 
Questionnaire; FF/VI, fluticasone furoate/vilanterol; OR, odds ratio; 
UC, usual care.</p></div>
<div class="footnote" id="tbl3fna">
<a href="#back-tbl3fna">a</a>Responders were defined as patients who self-scored 1 = no problems for a given dimension.</div>
<div class="footnote" id="tbl3fnb">
<a href="#back-tbl3fnb">b</a>Data based on last available on-treatment measurement (Week 52 or early withdrawal visit).</div>
<div class="footnote" id="tbl3fnc">
<a href="#back-tbl3fnc">c</a>ORs,
 95% CIs, and p-values were calculated using a logistic regression model
 adjusted for randomized treatment, asthma maintenance therapy at 
baseline per randomization stratification, ACT total score at baseline 
per randomization stratification, gender, age, and the relevant baseline
 EQ-5D-3L domain score.</div>
</div></div>
